Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Stamford; Andrew
Address:
Chatham Township, NJ
No. of patents:
22
Patents:












Patent Number Title Of Patent Date Issued
8278334 Cyclic amine BACE-1 inhibitors having a benzamide substituent October 2, 2012
Disclosed are compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## R is --C(O)--N(R.sup.27)(R.sup.28) or ##STR00003## and the remaining variables are as defined in the specification. Also disclose
8183252 Heterocyclic aspartyl protease inhibitors May 22, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.s
8168641 Aspartyl protease inhibitors May 1, 2012
Disclosed are compounds of formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R.sup.1, R.sup.2, R.sup.6, R.sup.7, R.sup.30 and R.sup.31 are as described above in the specification. Also disclosed is the method of inh
8110682 Preparation and use of compounds as aspartyl protease inhibitors February 7, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein A is a bond, --C(O)--, or --C(R.sup.3')(R.sup.4')--; X is --N(R.sup.1)-- or --C(R.sup.6)(R.sup.7)--; Y is --S(O).sub.2--, --C(.dbd.O)
8093254 Aspartyl protease inhibitors January 10, 2012
Disclosed are compounds of formula I (Chemical formula should be inserted here as it appears on abstract in paper form) Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.14, V, W, X, Y, Z,
7973067 Heterocyclic aspartyl protease inhibitors July 5, 2011
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.s
7910590 Cyclic amine bace-1 inhibitors having a heterocyclic substituent March 22, 2011
Disclosed are novel compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## X is --O--, --C(R .sup.14).sub.2-- or --N(R)--; Z is --C(R.sup.14).sub.2-- or --N(R)--; t is 0, 1, 2 or 3; each R and R.sup.2 is
7868000 Aspartyl protease inhibitors January 11, 2011
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein j, k, U, W, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7 and R.sup.7a are as described above in the specification.Also disclosed
7812013 Macrocyclic heterocyclic aspartyl protease inhibitors October 12, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt, solvate or ester thereof, wherein U, W, X, L, Y, M, Z, c, d, e, f, g, h, s, t, R.sup.1, R.sup.2, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13,
7763609 Heterocyclic aspartyl protease inhibitors July 27, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7759354 Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof July 20, 2010
The present application provides compounds of the Formula: ##STR00001## and stereoisomers, tautomers, or pharmaceutically acceptable salts and solvates thereof, wherein U, W, R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 in each formula (when present) are as defined in the specification, and
7759353 Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods July 20, 2010
Disclosed are certain substituted spiro iminopyrimidinones and other compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein U, W, A, R, R.sup.1, R.sup.2, R.sup.6a and R.sup.7, are as defined in the specifi
7713985 Adenosine A.sub.a2 receptor antagonists May 11, 2010
Compounds having the structural formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: X.sup.1 and X.sup.2 are 1-3 substituents independently selected from the group consisting of H, alkyl, halo, --CF.sub.3, --OCF.sub.3, alkoxy, --OH and --CN; n is 0, 1 or
7709492 Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A.sub.2a receptor antagonists May 4, 2010
Compounds having the structural formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H,
7700603 Heterocyclic aspartyl protease inhibitors April 20, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7662816 Cyclic amine BACE-1 inhibitors having a benzamide substituent February 16, 2010
Disclosed are compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## R is --C(O)--N(R.sup.27)(R.sup.28) or ##STR00003## and the remaining variables are as defined in the specification.Also disclosed are
7598250 Cyclic amine BACE-1 inhibitors having a heterocyclic substituent October 6, 2009
Disclosed are novel compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## X is --O--, --C(R.sup.14).sub.2-- or --N(R)--; Z is --C(R.sup.14).sub.2-- or --N(R)--; t is 0, 1, 2 or 3; each R and R.sup.2 is
7592348 Heterocyclic aspartyl protease inhibitors September 22, 2009
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7368449 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A.sub. May 6, 2008
Compounds having the structural formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R is ##STR00002## R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H, alkyl or alkoxyalkyl; R.sup.6 is H, alkyl, hydroxyalkyl or --CH.sub.2F; R.sup.7, R.sup.8 and R.s
7312223 Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatmen December 25, 2007
The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure ##STR00001## derivatives, and formulations thereof, and processes for preparing the same.Further disclosed are methods of treating a physiological disord
7268141 Xanthine phosphodiesterase V inhibitors September 11, 2007
A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: ##STR00001## For example, a representative compound of the inve
6897217 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a recepto May 24, 2005
Compounds having the structural formula I ##STR1##or a pharmaceutically acceptable salt thereof, wherein R is ##STR2## R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H, alkyl or alkoxyalkyl; R.sup.6 is H, alkyl, hydroxyalkyl or --CH.sub.2 F; R.sup.7, R.sup.8 and R.sup.9 are H










 
 
  Recently Added Patents
Peered proctoring
Method for driving bistable display device
Materials and methods for stress reduction in semiconductor wafer passivation layers
Lighting elements
Anti-slip strip for vehicle running boards
Asymmetric switching rectifier
PC secure video path
  Randomly Featured Patents
Hose clip
Reduction of errors during computation of inverse discrete cosine transform
Monitor adapter
Phosphonate fluorescent dyes and conjugates
Window cleaning fluid heating system having timer-controlled heater and differential input circuit
Method for forming an outer skin for a cover assembly
Linear attenuator for current-mode digital-to-analog converter (DAC) or the like
Automatic gain control circuit, data communication device and automatic gain control method
Digital processing system for binary addition/subtraction
Reprinting order processing system